When compared with the standard every-@-week paclitaxel arm , after a median follow-up of @ years , DFS significantly improved and overall survival ( OS ) marginally improved only for the weekly paclitaxel ( HR , @ ; P = @ and HR , @ ; P = @ , respectively ) and every-@-week docetaxel arms ( HR , @ ; P = @ and HR , @ ; P = @ , respectively ) .